## A to Z of Breast Cancer



## Dr R Soobrah


**Breast Surgeon** 



## **O**bjectives

- Describe common signs of BC
- Describe Investigations and importance of preoperative planning
- Operative management axilla & breast
- Other treatment modalities
- Future ...














# Inflammatory breast cancer





## nflammatory breast cancer

- Most aggressive form BC (~5%)
- Quick diagnosis!
- 30% have **stage IV** de novo disease [Stage IV Breast Cancer: 5-year survival ~ 15-20%]
- **chemotherapy** as the **first line** of treatment with the goal of downstaging the tumour to allow for definitive surgery (mastectomy + axillary node clearance)



## Risk factors

Risk cancer increases with age:


Age 25 ~ 1:20,000 (**0.005**%)

Age 30 ~ 1:2500

Age  $50 \sim 1:50$ 

Age 80 ~ 1:10

Lifetime risk =  $1:8 (\sim 12\%)$ 



## Table 1. Risk Factors for Breast Cancer

#### Nonmodifiable

- Female gender
- Age (>45 y)
- Genetic changes (mutations, BRCA)
- Family history of **Breast** / **Ovarian** Ca
- Personal history of breast cancer
- Race and ethnicity (White > African > Asian)
- Dense breast tissue
- Certain benign breast conditions<sup>a</sup>
- Lobular carcinoma in situ (LCIS)
- Menstrual periods (early menarche, late menopause)
- Previous chest radiation
- Diethylstilbestrol exposure

#### Modifiable


- Not having children (slight risk increase)
- Oral contraceptives (slight risk increase)
- Depo-Provera (slight risk increase)
- Hormone therapy after menopause (risk increase after 2 y of use)
- Breastfeeding (slight risk reduction)
- Alcohol consumption (risk increase)
- Obesity (risk increase)
- Physical exercise (risk reduction)

# Genes






- 10% hereditary
- BRCA 1/2
- TP53, PTEN, ....
- PALB2 (new gene)




# Triple Assessment



**Breast Cancer Diagnosis** 

### Frequency of cancers missed by each test



## Radiological Investigations

## Ultrasound scan






**Breasts and Axillae** 


## Mammography



Bilateral cancers: 5 – 10%

Multifocal cancers: 5 - 25%





# MRI scan


- Determine exact size of cancer
- Cancers not seen on USS/mammo
- High risk patients
- Dense breasts




# Biopsy


## **Under Ultrasound guidance**

Core biopsy




• FNA





#### **USS-guided FNA / Core biopsy**

**Less false-negative results** 



# Pathology report

• Invasive ductal carcinoma, invasive lobular carcinoma, ....

DCIS

Tumour size


• ER / PR


• Tumour grade (Grade1, Grade 2, Grade 3)

• Ki67

Tumour margins

# DCIS – Ductal Carcinoma in situ





- Grade 1
- Grade 2
- Grade 3

# Estrogen / Progesterone receptors (ER / PR)





 high levels of Ki-67 = aggressive tumour = poor prognosis

# Staging (5-year survival)

## Stages of Breast Cancer

- Metastatic breast cancer (MBC): ~5 10%
- limited role for surgery:
- More complications and deaths soon after cells in surgery for MBChethan inforgetar lierastage than 1 inch across. The educts with the surgery less than 2 inches extensive spread to immediate region

g cancer easts.

across. Cancer may also spread to auxiliary lymph nodes.

auxiliary or nearby lymph nodes. Possible dimpling, inflammation or change of skin color. of the breast.



Spread of cancer beyond the immediate region


of the breast.




vival SURVIVAL RATE




# Treatment






• The status of the axillary lymph nodes is one of the most important prognostic factors in women with early stage breast cancer.

## Sentinel Lymph Node Biopsy





**Sentinel Lymph Node biopsy** => standard care for staging patients who have clinically node-negative disease.






#### Localisation using radioactive tracer







Accuracy (combined technique) ~ 99%

# Surgery Axilla Breast

**Breast Conserving Surgery** 

Mastectomy






# Lumpectomy (wide local excision)


Remove cancer with a rim of normal breast tissue

#### **Breast-Conserving Surgery: Criteria**


- Small tumor-to-breast size
- Not more than one tumor in the same breast (unicentric)
- Negative tumor margins
- No contraindications for radiation










# Neo-adjuvant chemotherapy









## Wire-guided lumpectomy









D- Fat is re-injected using very fine cannulas


C- Fat is treated and centrifuged

#### Angelina Jolie


- Bilateral risk reducing mastectomy
- Survival benefit
- 1-2% will have occult cancer in mastectomy specimen
- Reduces risk of BC by ~90-95%



#### Breast Reconstruction



#### **Hormone Therapy**



 When used as adjuvant therapy after surgery in patients with early breast cancer it leads to Improved overall survival.

- 50% reduction in risk of developing cancer in other breast
- For ER-positive cancers, allocation to about 5 years of Tamoxifen reduces the annual breast cancer death rate by 31%

# Chemotherapy









500 mg


120 film-coated tablets



**Hoche** 









- 10 Table



### Chemo-prevention


 Tamoxifen and Raloxifene reduce the risk of breast cancer in women at increased risk of disease



 Tamoxifen – 50% reduction of BC in other breast for BRCA1/2 mutation carriers




#### Normal breast cancer cell



Normal amount of HER2 receptors send signals telling cells to grow and divide.<sup>1</sup>

#### Abnormal HER2+ breast cancer cell



Too many HER2 receptors send more signals, causing cells to grow too quickly.1

## Herceptin

- About 15 − 20% of all breast cancers are HER2+
- Significant correlation between HER2 overexpression and poor clinical outcome
- HERCEPTIN Reduces breast cancer recurrence by ~ 36% and mortality by ~ 40%

# Xray - Radiotherapy


• 50% reduction in any first recurrence




### Future



#### Tomosynthesis / 3D mammography





### Oncotype DX

Oncotype DX° reveals the underlying biology that changes treatment decisions 37% of the time


Uncover the Unexpected



### Oncotype DX

- Looks at the presence and activity of a group of genes within a woman's breast tumour to determine the likelihood of breast recurrence
- Predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer.
- **Recurrence Score** of 0 to 100 points. A low score indicates a low risk of recurrence and a high score indicates a high risk of recurrence

# Oncotype DX







#### Intra-operative Radiotherapy



#### Radiofrequency ablation






Capture basket—Five small RF-enabled wires deploy from the wand to circumscribe the lesion. As they proceed, they draw out five supporting elements which support and cradle the sample for withdrawal.

Intact Advance


#### Cryoablation






# Thank Jou







# Questions?




#### BRCA1 Breast Cancer Risk by Age





**Graph 1**. Blue bar indicates the average risk (percent chance) that a woman with a *BRCA1* mutation will develop breast cancer by each age noted across the bottom. The vertical line on each bar indicates a portion of the range of risks seen in different studies and is called the 95% confidence interval (Chan & Parmigiani 2007).





#### **Endocrine Therapy in Postmenopausal Patients**







#### Emitting chemicals that stimulate cell growth

#### Cancer cells stop growing

Oestrogen receptor Oestrogen


Oestrogen Oestrogen receptors





Oestrogen binds to oestrogen receptors Tamoxifen

Tamoxifen blocks
oestrogen receptors in
order to prevent oestrogen
from reaching the tumour.



#### **Breast Cancer Patient**

